Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 70, Issue 10, Pages 1290-1301Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.07.752
Keywords
cardiovascular disease; low-density lipoprotein; myalgia; myopathy; statin intolerance
Categories
Funding
- Akcea
- Amgen
- AstraZeneca
- Esperion
- Medicines Company
- Regeneron
- Valeant
- Sanofi
- Merck Sharp Dohme
- Pfizer
- Johnson Johnson
- General Electric
- Abbott Laboratories
- Abbvie
- Serapta
- Medtronic
Ask authors/readers for more resources
Statins are highly effective for preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C). However, many patients taking statins report muscle-related symptoms that prevent the use of guideline recommended doses. Patients with reported intolerance to statins have a high risk of cardiovascular events. Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing intolerable side effects that they attribute to statins. In this paper, the authors review definitions of statin intolerance, propose algorithms to better define statin intolerance, and describe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associated muscle symptoms. (J Am Coll Cardiol 2017;70:1290-301) (C) 2017 by the American College of Cardiology Foundation. Published by Elsevier. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available